AFM
CATX icon

Anson Funds Management’s Perspective Therapeutics CATX Stock Holding History

Anson Funds Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,318
Closed -$87K – 259
2020
Q4 		$87K Buy
+19,318
New +$85.3K 0.02% 165
2017
Q1 		– Sell
-40,490
Closed -$235K – 56
2016
Q4 		$235K Buy
+40,490
New +$248K 0.07% 73

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HPWM
Highland Private Wealth Management Bellevue, Washington $620M AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Anson Funds Management's CATX Position: Q1 2021 in Review

Anson Funds Management sold out of Perspective Therapeutics (CATX) in Q1 2021, closing a stake of 19,318 shares — an estimated $87K sold.

Anson Funds Management first reported a position in CATX in Q4 2016 and held it in 2 quarters. The position peaked at $235K in Q4 2016. 57 funds tracked by Wall St. Rank hold CATX as of Q1 2021.

  • Anson Funds Management reported no remaining Perspective Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Anson Funds Management sold 19,318 Perspective Therapeutics shares in Q1 2021, an estimated $87K.
  • Anson Funds Management first reported a position in Perspective Therapeutics in Q4 2016 and held it in 2 quarters.
  • Anson Funds Management's Perspective Therapeutics position peaked at $235K in Q4 2016.
  • 57 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2021.

Based on Anson Funds Management's 13F filing for Q1 2021, filed 14 May 2021.